Close Menu

stock delisting

The reverse stock split was done in order for BG Medicine to remain listed on Nasdaq, which had warned the firm in September of possible delisting action.

The company's stock failed to meet the exchange's $1 minimum bid requirement.

Alere missed the deadline to file its Form 10-Q as a result of having to restate its 2014 and interim financial results, prompting the warning from the NYSE.

The Australian firm regained compliance with a listing rule requiring a minimum $2.5 million in stockholder equity.

The company borrowed $2 million pursuant to an amendment to a $12 million credit agreement. It also said that it has until June 19 to meet certain listing requirements. 

The firm's shareholders will vote next month on the proposals, which are aimed at getting Nanosphere back in compliance with Nasdaq listing requirements.

The firm was not in compliance with minimum bid price and minimum stockholders' equity requirements to remain listed. 

The company has been told by Nasdaq that it falls short of a listing requirement for at least $2.5 million in stockholders' equity.

NEW YORK (GenomeWeb) – Response Genetics said on Tuesday that it has been notified by the Nasdaq that it is not in compliance with a requirement to continue listing its shares on the exchange.

NEW YORK (GenomeWeb News) – Nasdaq has notified BG Medicine that the company has not regained compliance with a listing requirement calling for at least $50 million in market value of its listed securities for continued listing on the exchange, BG Medicine said in a regulatory document.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.